Business
IceCure Receives High Level of Interest from Breast Surgeons at ASBrS 2025 Annual Meeting Following Recent Positive FDA Development on ProSense® Cryoablation
IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced it participated in the American Society of Breast Surgeons (ASBrS) 2025 Annual Meeting on April 30 – May 4, 2025 in Las Vegas.
About this update from Icecure Medical Ltd.
[{"type":"list","items":[{"val":[{"type":"text","content":"Breast surgeons expressed strong interest in participating in IceCure's planned post-market study for ProSense® in the treatment of early-stage breast cancer ","length":166,"tagName":"p"}]},{"val":[{"type":"text","content":"ICE3 study named as one of the "Best Papers of 2024" ","length":62,"tagName":"p"}]},{"val":[{"type":"text","content":"Cryoablation was mentioned favorably during the ASBrS Presidential Address ","length":74,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":302,"olType":false},{"type":"text","content":"CAESAREA, Israel, May 6, 2025 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced it participated in the American Society of Breast Surgeons (ASBrS) 2025 Annual Meeting on April 30 – May 4, 2025 in Las Vegas.","length":437,"tagName":"p"},{"type":"image","alt":"IceCure_Medical_Logo","displaySize":"","headline":null,"caption":"IceCure_Medical_Logo","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":200,"url":"https://media.zenfs.com/en/prnewswire.com/b733b9648e0c5c7b36e9d5bf48d042cc"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/2XUcwzAVdZCf5Oz2LQaIEw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTM1MztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/b733b9648e0c5c7b36e9d5bf48d042cc","width":400,"height":200}}},{"type":"text","content":""We couldn't be more pleased with the high level of interest in ProSense® at the ASBrS 2025 Annual Meeting and the reaction of breast surgeons to the recent positive U.S. Food and Drug Administration ("FDA") development regarding our cryoablation system's pathway to marketing authorization," stated Eyal Shamir, IceCure's Chief Executive Officer. "A large number of doctors approached our booth, asking how they could participate in our planned post-market study and how they could offer ProSense® to their patients following marketing authorization. We were fortunate that cryoablation for breast cancer was included in prominent presentations by thought leaders, including in the Presidential Address and the Best Papers of 2024 ...